(Q38066606)

28 August 2017

1 reference

title

Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders (English)

1 reference

28 August 2017

1 reference

Werner J Geldenhuys

1

1 reference

PubMed ID

23231597

28 August 2017

Cornelis J Van der Schyf

series ordinal

2

1 reference

PubMed ID

23231597

28 August 2017

language of work or name

English

0 references

publication date

12 December 2012

1 reference

Expert Opinion on Drug Discovery

28 August 2017

1 reference

28 August 2017

8

1 reference

28 August 2017

2

1 reference

28 August 2017

115-129

1 reference

The emergence of designed multiple ligands for neurodegenerative disorders

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

From magic bullets to designed multiple ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Industrial toxicants and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

The mechanisms of 6-hydroxydopamine-induced astrocyte death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Misfolded proteins in Alzheimer's disease and type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Ebselen inhibits iron-induced tau phosphorylation by attenuating DMT1 up-regulation and cellular iron uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Ironing out tau's role in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Biology of mitochondria in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Mitochondria in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Pharmacology and structure-activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

The structure and ion channel activity of 6-benzylamino-3-hydroxyhexa-cyclo[6.5.0.0(3,7).0(4,12).0(5,10).0(9,13]tridecane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Structure-activity relationships of pentacycloundecylamines at the N-methyl-d-aspartate receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Trishomocubanes: novel sigma-receptor ligands modulate amphetamine-stimulated [3H]dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Oxo-bridged isomers of aza-trishomocubane sigma (sigma) receptor ligands: Synthesis, in vitro binding, and molecular modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

In vitro and in vivo characterisation of [3H]ANSTO-14 binding to the sigma 1 binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Trishomocubanes: novel sigma ligands modulate cocaine-induced behavioural effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Influence of trishomocubanes on sigma receptor binding of N-(1-benzyl-piperidin-4-yl)-4-[123I]iodobenzamide in vivo in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Natural products of dietary origin as lead compounds in virtual screening and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Small molecule modulators of copper-induced Abeta aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Novel stilbenes as probes for amyloid plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-β species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Exploring the reactivity of flavonoid compounds with metal-associated amyloid-β species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Myricetin: a naturally occurring regulator of metal-induced amyloid-β aggregation and neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

The therapeutic potential of monoamine oxidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Resveratrol, a red wine polyphenol, protects dopaminergic neurons in MPTP-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Caffeine for treatment of Parkinson disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Adenosine receptors as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Emerging adenosine receptor agonists: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Aza-analogs of 8-styrylxanthines as A2A-adenosine receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Antidiabetes Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Privileged Scaffolds or Promiscuous Binders: A Comparative Study on Rhodanines and Related Heterocycles in Medicinal Chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

PPAR-gamma: therapeutic target for ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

The neuroprotective mechanism of action of the multimodal drug ladostigil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Pharmacological aspects of (-)-deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

R-deprenyl: pharmacological spectrum of its activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Acteylcholinesterase inhibitor rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Investigation of the photostability properties of memoquin, a quinone derivative for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Alzheimer's disease: new approaches to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Structure-activity relationships of memoquin: Influence of the chain chirality in the multi-target mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Polyamine conjugation of curcumin analogues toward the discovery of mitochondria-directed neuroprotective agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Designing multiple ligands - medicinal chemistry strategies and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Designed multiple ligands. An emerging drug discovery paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Blood-brain barrier delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

NMDA receptor pathways as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Iron, brain ageing and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

Affinity of 1-aminoadamantanes for the σ binding site in post-mortem human frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.744746

10.1517/17460441.2013.744746

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23231597